A really clear message from Fiona Bride at Financial Times Global Pharma & Biotech Conference this morning: 1 - let’s build on our strength as a pro-innovation health system that gets cutting edge therapies to patients 2- let’s do our best for taxpayers by using clinically effective medicines available at lower cost 3- let’s not shy away from the challenge of improving uptake of treatments for large eligible populations, but use tech to lean-in and evolve
A pleasure to talk this morning with Laura Hughes, Public Policy Correspondent at the FT about how the NHS can make innovation work for patients and taxpayers. Our ambition is clear: we want to build on our early leadership to become the most pro-ATMP healthcare system worldwide, and we recognise that to achieve this, we need to become the most pro-biosimilars healthcare system. Building on the NHS’ existing strength in generic prescribing, through rapid adoption of biosimilars over the next 5 years we can deliver up to £1bn in financial headroom will enable continued adoption and wider uptake of cutting-edge branded medicines, capitalising on the VPAG agreement between the health service, government, and pharmaceutical industry. Speaking just 24hrs after confirmation that the NHS will be full partner in a relaunched ILAP (https://lnkd.in/eaK5pu7v) provides a real signal of intent, with an end-to-end access pathway from clinical trials to patient access being a unique UK offer to industry. We’re not ignoring the challenges that persist. We have to evolve the way that we bring medicines to patients; taking advantage of digital technologies to innovate services that will result in expanding access and improving uptake, while recognising the reality that front-line colleagues are already delivering record levels of activity, to meet record demand. #FTLive